MX2014012285A - Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza. - Google Patents

Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza.

Info

Publication number
MX2014012285A
MX2014012285A MX2014012285A MX2014012285A MX2014012285A MX 2014012285 A MX2014012285 A MX 2014012285A MX 2014012285 A MX2014012285 A MX 2014012285A MX 2014012285 A MX2014012285 A MX 2014012285A MX 2014012285 A MX2014012285 A MX 2014012285A
Authority
MX
Mexico
Prior art keywords
methods
treating
inhibitor
virus infection
influenza virus
Prior art date
Application number
MX2014012285A
Other languages
English (en)
Spanish (es)
Inventor
Ngambo Lisa A Purcell
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014012285A publication Critical patent/MX2014012285A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2014012285A 2012-04-16 2013-04-15 Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza. MX2014012285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624519P 2012-04-16 2012-04-16
US201361759469P 2013-02-01 2013-02-01
PCT/US2013/036522 WO2013158516A1 (en) 2012-04-16 2013-04-15 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

Publications (1)

Publication Number Publication Date
MX2014012285A true MX2014012285A (es) 2015-04-13

Family

ID=48184523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012285A MX2014012285A (es) 2012-04-16 2013-04-15 Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza.

Country Status (14)

Country Link
US (1) US9498529B2 (enExample)
EP (2) EP2838558A1 (enExample)
JP (2) JP6446355B2 (enExample)
KR (1) KR20150008383A (enExample)
CN (1) CN104244978A (enExample)
AU (2) AU2013249577A1 (enExample)
BR (1) BR112014025339A8 (enExample)
CA (2) CA3219083A1 (enExample)
HK (1) HK1202817A1 (enExample)
MX (1) MX2014012285A (enExample)
NZ (1) NZ631105A (enExample)
SG (1) SG11201405163RA (enExample)
WO (1) WO2013158516A1 (enExample)
ZA (1) ZA201406194B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3895529B1 (en) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
BR112020015112A2 (pt) * 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos
EP4103619A1 (en) * 2020-02-10 2022-12-21 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195119A1 (en) * 2020-03-24 2021-09-30 Corcept Therapeutics Incorporated Methods of reducing the risk of, severity of, and treating coronavirus infections
EP3964207A1 (en) 2020-09-02 2022-03-09 Christian-Albrechts-Universität zu Kiel Antiviral pharmaceutical composition for topical administration
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
BRPI0606432A2 (pt) * 2005-01-07 2009-06-30 Lexicon Pharmaceuticals Inc anticorpos monoclonais contra angptl4
US20070191322A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Microbial Compositions and Methods of Use
JP2008247864A (ja) * 2007-03-30 2008-10-16 Univ Of Tokushima モザイクセリンプロテアーゼ、mspとその用途
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および/または予防薬
EP2445963B1 (en) 2009-06-22 2013-10-30 Borealis AG Automotive interior article with reduced smell
EP4083075A1 (en) * 2012-02-15 2022-11-02 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives

Also Published As

Publication number Publication date
HK1202817A1 (en) 2015-10-09
SG11201405163RA (en) 2014-09-26
CA2869010A1 (en) 2013-10-24
JP2018048169A (ja) 2018-03-29
AU2018200265B2 (en) 2019-07-18
WO2013158516A1 (en) 2013-10-24
BR112014025339A8 (pt) 2018-01-16
BR112014025339A2 (pt) 2013-10-24
EP2838558A1 (en) 2015-02-25
US20130273070A1 (en) 2013-10-17
EP3536342A1 (en) 2019-09-11
AU2018200265A1 (en) 2018-02-01
US9498529B2 (en) 2016-11-22
KR20150008383A (ko) 2015-01-22
CA3219083A1 (en) 2013-10-24
JP6446355B2 (ja) 2018-12-26
AU2013249577A1 (en) 2014-10-02
CN104244978A (zh) 2014-12-24
JP2015516975A (ja) 2015-06-18
ZA201406194B (en) 2016-08-31
NZ631105A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
HK1202817A1 (en) Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
MX387277B (es) Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
BR112012019042A2 (pt) "inibidores de serina protease tipo tripsina, e sua preparação e uso".
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
IN2014CN03113A (enExample)
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CO6660439A2 (es) Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido
AU2014310935B2 (en) Combination vaccine
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201290897A1 (ru) Вакцины для пандемического гриппа
EA201400235A1 (ru) Вакцины против гриппа на основе н5
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
EA201590460A1 (ru) Способ и средство для лечения и профилактики заболеваний, вызываемых (+)рнк-содержащими вирусами
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EP4477231A3 (en) Combination vaccine

Legal Events

Date Code Title Description
FG Grant or registration